Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 250

1.

Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma.

Massihnia D, Funel N, Leon L, Castiglia M, Perez A, Barraco N, Listì A, Galvano A, Passiglia F, Guarini A, Calò V, Rizzo S, Castellana L, Giovannetti E, Russo A.

Ann Oncol. 2017 Oct;28 Suppl 6:vi45. doi: 10.1093/annonc/mdx425.003. No abstract available.

PMID:
31962717
2.

Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function.

Van Der Steen N, Keller K, Dekker H, Porcelli L, Honeywell RJ, Van Meerloo J, Musters RJP, Kathmann I, Frampton AE, Liu DSK, Ruijtenbeek R, Rolfo C, Pauwels P, Giovannetti E, Peters GJ.

J Cell Physiol. 2020 Jan 20. doi: 10.1002/jcp.29463. [Epub ahead of print]

PMID:
31960422
3.

3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma.

Cascioferro S, Li Petri G, Parrino B, El Hassouni B, Carbone D, Arizza V, Perricone U, Padova A, Funel N, Peters GJ, Cirrincione G, Giovannetti E, Diana P.

Molecules. 2020 Jan 14;25(2). pii: E329. doi: 10.3390/molecules25020329.

4.

Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach.

Le Large TYS, Meijer LL, Paleckyte R, Boyd LNC, Kok B, Wurdinger T, Schelfhorst T, Piersma SR, Pham TV, van Grieken NCT, Zonderhuis BM, Daams F, van Laarhoven HWM, Bijlsma MF, Jimenez CR, Giovannetti E, Kazemier G.

Oncologist. 2020 Jan 14. doi: 10.1634/theoncologist.2019-0680. [Epub ahead of print]

5.

The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies.

Van Der Steen N, Zwaenepoel K, Mazzaschi G, A Luirink R, P Geerke D, Op de Beeck K, Hermans C, Tiseo M, Van Schil P, Lardon F, Germonpré P, Rolfo C, Giovannetti E, J Peters G, Pauwels P.

Molecules. 2019 Dec 4;24(24). pii: E4443. doi: 10.3390/molecules24244443.

6.

CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage.

El Hassouni B, Mantini G, Immordino B, Peters GJ, Giovannetti E.

Molecules. 2019 Dec 4;24(24). pii: E4445. doi: 10.3390/molecules24244445.

7.

Diagnosing pancreatic ductal adenocarcinoma using plasma extracellular vesicle RNA profiles.

Frampton AE, Giovannetti E.

Gut. 2019 Dec 4. pii: gutjnl-2019-319896. doi: 10.1136/gutjnl-2019-319896. [Epub ahead of print] No abstract available.

PMID:
31801873
8.

Tumor microbiome: Pancreatic cancer and duodenal fluids contain multitudes, …but do they contradict themselves?

Meijer LL, Zwart ES, Brandt BW, Mebius R, Deng D, Giovannetti E, Zaura E, Kazemier G.

Crit Rev Oncol Hematol. 2019 Dec;144:102824. doi: 10.1016/j.critrevonc.2019.102824. Epub 2019 Nov 2. No abstract available.

PMID:
31731215
9.

New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism.

Capula M, Mantini G, Funel N, Giovannetti E.

Expert Rev Clin Pharmacol. 2019 Dec;12(12):1081-1090. doi: 10.1080/17512433.2019.1693256. Epub 2019 Nov 24. Review.

PMID:
31721608
10.

Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on 'preclinical and early-phase clinical pharmacology'.

Leonetti A, Boyd L, Giuliani J, Giovannetti E, Garajová I.

Expert Rev Clin Pharmacol. 2019 Nov;12(11):1033-1036. doi: 10.1080/17512433.2019.1683446. Epub 2019 Oct 30. Review.

PMID:
31633383
11.

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.

Leonetti A, Wever B, Mazzaschi G, Assaraf YG, Rolfo C, Quaini F, Tiseo M, Giovannetti E.

Drug Resist Updat. 2019 Sep;46:100644. doi: 10.1016/j.drup.2019.100644. Epub 2019 Sep 17.

PMID:
31585395
12.

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M.

Br J Cancer. 2019 Oct;121(9):725-737. doi: 10.1038/s41416-019-0573-8. Epub 2019 Sep 30. Review.

PMID:
31564718
13.

HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.

Moosavi F, Giovannetti E, Saso L, Firuzi O.

Crit Rev Clin Lab Sci. 2019 Dec;56(8):533-566. doi: 10.1080/10408363.2019.1653821. Epub 2019 Sep 12.

PMID:
31512514
14.

PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition.

Cretella D, Digiacomo G, Giovannetti E, Cavazzoni A.

Cancers (Basel). 2019 Sep 6;11(9). pii: E1318. doi: 10.3390/cancers11091318. Review.

15.

The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies.

El Hassouni B, Granchi C, Vallés-Martí A, Supadmanaba IGP, Bononi G, Tuccinardi T, Funel N, Jimenez CR, Peters GJ, Giovannetti E, Minutolo F.

Semin Cancer Biol. 2019 Aug 21. pii: S1044-579X(19)30180-4. doi: 10.1016/j.semcancer.2019.08.025. [Epub ahead of print] Review.

PMID:
31445217
16.

Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors.

Meijer LL, Puik JR, Le Large TYS, Heger M, Dijk F, Funel N, Wurdinger T, Garajová I, van Grieken NCT, van de Wiel MA, Giovannetti E, Kazemier G.

Cancers (Basel). 2019 Aug 15;11(8). pii: E1181. doi: 10.3390/cancers11081181.

17.

Breastfeeding during R-CHOP chemotherapy: please abstain!

Codacci-Pisanelli G, Honeywell RJ, Asselin N, Bellettini G, Peters GJ, Giovannetti E, Peccatori FA.

Eur J Cancer. 2019 Sep;119:107-111. doi: 10.1016/j.ejca.2019.07.012. Epub 2019 Aug 19. No abstract available.

PMID:
31437753
18.

Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression.

Ottaviani S, Stebbing J, Frampton AE, Zagorac S, Krell J, de Giorgio A, Trabulo SM, Nguyen VTM, Magnani L, Feng H, Giovannetti E, Funel N, Gress TM, Jiao LR, Lombardo Y, Lemoine NR, Heeschen C, Castellano L.

Nat Commun. 2019 Aug 14;10(1):3738. doi: 10.1038/s41467-019-11752-2.

19.

Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivatives Against Pancreatic Cancer Cells.

Li Petri G, Cascioferro S, El Hassouni B, Carbone D, Parrino B, Cirrincione G, Peters GJ, Diana P, Giovannetti E.

Anticancer Res. 2019 Jul;39(7):3615-3620. doi: 10.21873/anticanres.13509.

PMID:
31262887
20.

Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer.

El Hassouni B, Infante J, Mantini G, Ricci C, Funel N, Giovannetti E, Peters GJ.

Anticancer Res. 2019 Jul;39(7):3609-3614. doi: 10.21873/anticanres.13508.

PMID:
31262886
21.

To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology.

El Hassouni B, Mantini G, Li Petri G, Capula M, Boyd L, Weinstein HNW, Vallés-Marti A, Kouwenhoven MCM, Giovannetti E, Westerman BA, Peters GJ; EORTC PAMM Group.

Anticancer Res. 2019 Jul;39(7):3303-3309. doi: 10.21873/anticanres.13472. Review.

PMID:
31262850
22.

Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment.

Le Large TYS, El Hassouni B, Funel N, Kok B, Piersma SR, Pham TV, Olive KP, Kazemier G, van Laarhoven HWM, Jimenez CR, Bijlsma MF, Giovannetti E.

Ther Adv Med Oncol. 2019 May 10;11:1758835919841233. doi: 10.1177/1758835919841233. eCollection 2019.

23.

Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?

Liu DSK, Mato Prado M, Giovannetti E, Jiao LR, Krell J, Frampton AE.

Expert Rev Mol Diagn. 2019 Jul;19(7):553-558. doi: 10.1080/14737159.2019.1622414. Epub 2019 Jun 10. No abstract available.

PMID:
31159604
24.

Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract.

Roos E, Soer EC, Klompmaker S, Meijer LL, Besselink MG, Giovannetti E, Heger M, Kazemier G, Klümpen HJ, Takkenberg RB, Wilmink H, Würdinger T, Dijk F, van Gulik TM, Verheij J, van de Vijver MJ.

Crit Rev Oncol Hematol. 2019 Aug;140:8-16. doi: 10.1016/j.critrevonc.2019.05.011. Epub 2019 May 24.

PMID:
31158800
25.

Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.

Van Den Borg R, Leonetti A, Tiseo M, Giovannetti E, Peters GJ.

Expert Rev Anticancer Ther. 2019 Jun;19(6):461-471. doi: 10.1080/14737140.2019.1624530. Epub 2019 May 31.

PMID:
31148500
26.

Pharmacogenetics of treatments for pancreatic cancer.

El Hassouni B, Li Petri G, Liu DSK, Cascioferro S, Parrino B, Hassan W, Diana P, Ali A, Frampton AE, Giovannetti E.

Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):437-447. doi: 10.1080/17425255.2019.1620731. Epub 2019 May 24. Review.

PMID:
31100206
27.

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line.

Van Der Steen N, Leonetti A, Keller K, Dekker H, Funel N, Lardon F, Ruijtenbeek R, Tiseo M, Rolfo C, Pauwels P, Peters GJ, Giovannetti E.

Biochem Pharmacol. 2019 Aug;166:128-138. doi: 10.1016/j.bcp.2019.05.014. Epub 2019 May 10.

PMID:
31078602
28.

Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells.

Firuzi O, Che PP, El Hassouni B, Buijs M, Coppola S, Löhr M, Funel N, Heuchel R, Carnevale I, Schmidt T, Mantini G, Avan A, Saso L, Peters GJ, Giovannetti E.

Cancers (Basel). 2019 May 8;11(5). pii: E638. doi: 10.3390/cancers11050638.

29.

Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.

Leonetti A, Facchinetti F, Minari R, Cortellini A, Rolfo CD, Giovannetti E, Tiseo M.

Cell Oncol (Dordr). 2019 Jun;42(3):261-273. doi: 10.1007/s13402-019-00441-3. Epub 2019 Apr 9. Review.

PMID:
30968324
30.

RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment.

Balboni B, El Hassouni B, Honeywell RJ, Sarkisjan D, Giovannetti E, Poore J, Heaton C, Peterson C, Benaim E, Lee YB, Kim DJ, Peters GJ.

Expert Opin Investig Drugs. 2019 Apr;28(4):311-322. doi: 10.1080/13543784.2019.1583742. Epub 2019 Mar 16. Review.

PMID:
30879349
31.

Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?

Peters GJ, Giovannetti E, Honeywell RJ, Ciccolini J.

Br J Clin Pharmacol. 2019 Jun;85(6):1213-1214. doi: 10.1111/bcp.13921. Epub 2019 Apr 23. No abstract available.

32.

2,6-Disubstituted imidazo[2,1-b][1,3,4]thiadiazole derivatives as potent staphylococcal biofilm inhibitors.

Cascioferro S, Parrino B, Petri GL, Cusimano MG, Schillaci D, Di Sarno V, Musella S, Giovannetti E, Cirrincione G, Diana P.

Eur J Med Chem. 2019 Apr 1;167:200-210. doi: 10.1016/j.ejmech.2019.02.007. Epub 2019 Feb 10.

PMID:
30772604
33.

Noncoding Rnas Emerging as Novel Biomarkers in Pancreatic Cancer.

Garajová I, Balsano R, Tommasi C, Giovannetti E.

Curr Pharm Des. 2018;24(39):4601-4604. doi: 10.2174/1381612825666190119125804. Review.

PMID:
30659532
34.

Combined exosomal RNA and circulating tumor DNA for epidermal growth factor mutation detection in non-small cell lung cancer.

Lazzari C, Gregorc V, Cangi MG, Giovannetti E, Bulotta A, Santarpia M.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4023-S4027. doi: 10.21037/jtd.2018.10.17. No abstract available.

35.

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.

Sciarrillo R, Wojtuszkiewicz A, El Hassouni B, Funel N, Gandellini P, Lagerweij T, Buonamici S, Blijlevens M, Zeeuw van der Laan EA, Zaffaroni N, Deraco M, Kusamura S, Würdinger T, Peters GJ, Molthoff CFM, Jansen G, Kaspers GJL, Cloos J, Giovannetti E.

EBioMedicine. 2019 Jan;39:215-225. doi: 10.1016/j.ebiom.2018.12.025. Epub 2018 Dec 20.

36.

MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.

Leonetti A, Assaraf YG, Veltsista PD, El Hassouni B, Tiseo M, Giovannetti E.

Drug Resist Updat. 2019 Jan;42:1-11. doi: 10.1016/j.drup.2018.11.002. Epub 2018 Nov 28. Review.

PMID:
30544036
37.

Targeting the Ribosome Biogenesis Key Molecule Fibrillarin to Avoid Chemoresistance.

El Hassouni B, Sarkisjan D, Vos JC, Giovannetti E, Peters GJ.

Curr Med Chem. 2019;26(33):6020-6032. doi: 10.2174/0929867326666181203133332. Review.

PMID:
30501594
38.

Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.

Tibaldi C, Camerini A, Tiseo M, Mazzoni F, Barbieri F, Vittimberga I, Brighenti M, Boni L, Baldini E, Gilli A, Honeywell R, Chartoire M, Peters GJ, Giovannetti E; Italian Oncological Group of Clinical Research (GOIRC).

Br J Cancer. 2018 Nov;119(11):1326-1331. doi: 10.1038/s41416-018-0307-3. Epub 2018 Nov 8.

39.

Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.

Meijer LL, Garajová I, Caparello C, Le Large TYS, Frampton AE, Vasile E, Funel N, Kazemier G, Giovannetti E.

Ann Surg. 2018 Dec 9. doi: 10.1097/SLA.0000000000003084. [Epub ahead of print]

PMID:
30394883
40.

The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine.

Choy ATF, Carnevale I, Coppola S, Meijer LL, Kazemier G, Zaura E, Deng D, Giovannetti E.

Expert Rev Mol Diagn. 2018 Dec;18(12):1005-1009. doi: 10.1080/14737159.2018.1544495. Epub 2018 Nov 9.

PMID:
30392417
41.

Synthetic small molecules as anti-biofilm agents in the struggle against antibiotic resistance.

Parrino B, Schillaci D, Carnevale I, Giovannetti E, Diana P, Cirrincione G, Cascioferro S.

Eur J Med Chem. 2019 Jan 1;161:154-178. doi: 10.1016/j.ejmech.2018.10.036. Epub 2018 Oct 17. Review.

PMID:
30347328
42.

Multidrug-resistant transporter expression does not always result in drug resistance.

Le Large TYS, El Hassouni B, Kazemier G, Piersma SR, van Laarhoven HWM, Bijlsma MF, Jimenez CR, Giovannetti E.

Cancer Sci. 2018 Oct;109(10):3360-3362. doi: 10.1111/cas.13756. Epub 2018 Sep 8. No abstract available.

43.

Liquid biopsies to optimize therapeutic efficacy in unresponsive lung cancer patients.

Santarpia M, Funel N, Ali A, Giovannetti E.

Expert Opin Drug Metab Toxicol. 2018 Aug;14(8):761-763. doi: 10.1080/17425255.2018.1491965. Epub 2018 Jul 4. No abstract available.

PMID:
29933706
44.

Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.

Petri GL, Cascioferro S, Parrino B, Peters GJ, Diana P, Giovannetti E.

Pharmacogenomics. 2018 Jul 1;19(10):811-814. doi: 10.2217/pgs-2018-0071. Epub 2018 Jun 19. No abstract available.

45.

Aminopeptidase antibodies in mesothelioma: new wine deserves new sacks.

van Meerbeeck JP, Jansen G, Giovannetti E, Peters GJ.

Eur Respir J. 2018 May 24;51(5). pii: 1800817. doi: 10.1183/13993003.00817-2018. Print 2018 May. No abstract available.

46.

TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression.

Ottaviani S, Stebbing J, Frampton AE, Zagorac S, Krell J, de Giorgio A, Trabulo SM, Nguyen VTM, Magnani L, Feng H, Giovannetti E, Funel N, Gress TM, Jiao LR, Lombardo Y, Lemoine NR, Heeschen C, Castellano L.

Nat Commun. 2018 May 10;9(1):1845. doi: 10.1038/s41467-018-03962-x. Erratum in: Nat Commun. 2019 Aug 14;10(1):3738.

47.

Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.

Frampton AE, Prado MM, López-Jiménez E, Fajardo-Puerta AB, Jawad ZAR, Lawton P, Giovannetti E, Habib NA, Castellano L, Stebbing J, Krell J, Jiao LR.

Oncotarget. 2018 Apr 10;9(27):19006-19013. doi: 10.18632/oncotarget.24873. eCollection 2018 Apr 10.

48.

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

van Zweeden AA, van Groeningen CJ, Honeywell RJ, Giovannetti E, Ruijter R, Smorenburg CH, Giaccone G, Verheul HMW, Peters GJ, van der Vliet HJ.

Cancer Chemother Pharmacol. 2018 Jul;82(1):39-48. doi: 10.1007/s00280-018-3588-6. Epub 2018 Apr 25.

49.

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.

Toffalorio F, Santarpia M, Radice D, Jaramillo CA, Spitaleri G, Manzotti M, Catania C, Jordheim LP, Pelosi G, Peters GJ, Tibaldi C, Funel N, Spaggiari L, de Braud F, De Pas T, Giovannetti E.

Oncotarget. 2018 Feb 16;9(23):16437-16450. doi: 10.18632/oncotarget.24505. eCollection 2018 Mar 27.

50.

Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.

Passiglia F, Caglevic C, Giovannetti E, Pinto JA, Manca P, Taverna S, Listì A, Gil-Bazo I, Raez LE, Russo A, Rolfo C.

Semin Cancer Biol. 2018 Oct;52(Pt 2):259-268. doi: 10.1016/j.semcancer.2018.01.015. Epub 2018 Jan 31. Review.

PMID:
29391205

Supplemental Content

Loading ...
Support Center